These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32718195)

  • 1. Engineered liposomes bearing camptothecin analogue for tumour targeting:
    Saraf S; Jain A; Tiwari A; Verma A; Jain SK
    J Liposome Res; 2021 Dec; 31(4):326-341. PubMed ID: 32718195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. pH-sensitive liposomes bearing a chemotherapeutic agent and a natural apoptosis modulator for effective intracellular delivery to the solid tumor.
    Saraf S; Jain SK
    Drug Deliv Transl Res; 2023 Dec; 13(12):2961-2981. PubMed ID: 37306925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of pH and ring-opening hydrolysis kinetics on liposomal release of topotecan.
    Fugit KD; Anderson BD
    J Control Release; 2014 Jan; 174():88-97. PubMed ID: 24231406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH.
    Gabr A; Kuin A; Aalders M; El-Gawly H; Smets LA
    Cancer Res; 1997 Nov; 57(21):4811-6. PubMed ID: 9354443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan.
    Subramanian D; Muller MT
    Oncol Res; 1995; 7(9):461-9. PubMed ID: 8835290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Camptothecin analogues with enhanced antitumor activity at acidic pH.
    Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME
    Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
    Sorensen M; Sehested M; Jensen PB
    Br J Cancer; 1995 Aug; 72(2):399-404. PubMed ID: 7640225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor microenvironment responsive VEGF-antibody functionalized pH sensitive liposomes of docetaxel for augmented breast cancer therapy.
    Jain S; Deore SV; Ghadi R; Chaudhari D; Kuche K; Katiyar SS
    Mater Sci Eng C Mater Biol Appl; 2021 Feb; 121():111832. PubMed ID: 33579470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic potential of camptothecin and topotecan.
    Clements MK; Jones CB; Cumming M; Daoud SS
    Cancer Chemother Pharmacol; 1999; 44(5):411-6. PubMed ID: 10501915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topotecan hydrochloride liposomes incorporated into thermosensitive hydrogel for sustained and efficient in situ therapy of H22 tumor in Kunming mice.
    Xing J; Qi X; Jiang Y; Zhu X; Zhang Z; Qin X; Wu Z
    Pharm Dev Technol; 2015 Nov; 20(7):812-819. PubMed ID: 24909735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Polymer-Lipid Hybrid Nanoparticle for the Improvement of Topotecan Hydrochloride Physicochemical Properties.
    Silva EJ; Souza LG; Silva LAD; Taveira SF; Guilger RC; Liao LM; Queiroz Junior LHK; Santana MJ; Marreto RN
    Curr Drug Deliv; 2018; 15(7):979-986. PubMed ID: 29243576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.
    Hendricks CB; Rowinsky EK; Grochow LB; Donehower RC; Kaufmann SH
    Cancer Res; 1992 Apr; 52(8):2268-78. PubMed ID: 1348448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caffeine prevents apoptosis and cell cycle effects induced by camptothecin or topotecan in HL-60 cells.
    Traganos F; Kapuscinski J; Gong J; Ardelt B; Darzynkiewicz RJ; Darzynkiewicz Z
    Cancer Res; 1993 Oct; 53(19):4613-8. PubMed ID: 8402636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. F7 and topotecan co-loaded thermosensitive liposome as a nano-drug delivery system for tumor hyperthermia.
    Du C; Li S; Li Y; Galons H; Guo N; Teng Y; Zhang Y; Li M; Yu P
    Drug Deliv; 2020 Dec; 27(1):836-847. PubMed ID: 32508162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo studies of different liposomes containing topotecan.
    Hao YL; Deng YJ; Chen Y; Wang XM; Zhong HJ; Suo XB
    Arch Pharm Res; 2005 May; 28(5):626-35. PubMed ID: 15974453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor.
    Lee JH; Lee JM; Kim JK; Ahn SK; Lee SJ; Kim MY; Jew SS; Park JG; Hong CI
    Arch Pharm Res; 1998 Oct; 21(5):581-90. PubMed ID: 9875499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer.
    Patankar NA; Waterhouse D; Strutt D; Anantha M; Bally MB
    Invest New Drugs; 2013 Feb; 31(1):46-58. PubMed ID: 22615060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
    Rowinsky EK; Adjei A; Donehower RC; Gore SD; Jones RJ; Burke PJ; Cheng YC; Grochow LB; Kaufmann SH
    J Clin Oncol; 1994 Oct; 12(10):2193-203. PubMed ID: 7931489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
    Dadashzadeh S; Vali AM; Rezaie M
    Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoskeletal interference - A new mode of action for the anticancer drugs camptothecin and topotecan.
    Wang X; Tanaka M; Krstin S; Peixoto HS; Moura CCM; Wink M
    Eur J Pharmacol; 2016 Oct; 789():265-274. PubMed ID: 27474470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.